GSK's Avodart reduces prostate cancer cases in pivotal Phase III prevention trial
This article was originally published in Scrip
GlaxoSmithKline's drug Avodart (dutasteride) reduced the numbers of prostate cancer cases in men at increased risk of disease who took it compared with those who received placebo in a registrational Phase III trial with over 8,000 men, and could lessen the numbers of men who receive treatment for the disease.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.